HEK293/Human GLP-1 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0106D | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor primarily activated by the gut hormone GLP-1. It is widely distributed in various tissues including pancreatic β-cells, the brain (particularly appetite-regulating hypothalamic centers), gastrointestinal tract, heart, and vascular endothelium. Its core function is to mediate the potent “incretin effect”: upon elevated blood glucose, it stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and induces satiety via the central nervous system, thereby exerting multi-faceted glucose-lowering and weight-reducing effects. Owing to these crucial physiological roles, GLP-1R has become a first-line therapeutic target for type 2 diabetes and obesity. Its agonists (e.g., semaglutide) not only effectively control blood glucose and body weight but also demonstrate additional cardiovascular and renal protective benefits.
Screeningbio’s HEK293/Human GLP-1 cell line overexpress GLP1R and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | GLP1R |
Accession Number | NM_002062 (Hs) |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor primarily activated by the gut hormone GLP-1.
It is widely distributed in various tissues including pancreatic β-cells, the brain (particularly appetite-regulating hypothalamic centers), gastrointestinal tract, heart, and vascular endothelium. Its core function is to mediate the potent “incretin effect”: upon elevated blood glucose, it stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and induces satiety via the central nervous system, thereby exerting multi-faceted glucose-lowering and weight-reducing effects.
Owing to these crucial physiological roles, GLP-1R has become a first-line therapeutic target for type 2 diabetes and obesity. Its agonists (e.g., semaglutide) not only effectively control blood glucose and body weight but also demonstrate additional cardiovascular and renal protective benefits.